A Validated Prognostic Nomogram for Patients with H3 K27M-mutant Diffuse Midline Glioma

Overview

Journal Sci Rep

Specialty Science

Date 2023 Jun 20

PMID 37340065

Authors

Youheng Peng

Yanming Ren

Bowen Huang

Jun Tang

Yan Jv

Qing Mao

Yanhui Liu

Yinjie Lei

Yuekang Zhang

Affiliations

Soon will be listed here.

Abstract

H3 K27M-mutant diffuse midline glioma (H3 K27M-mt DMG) is a rare, highly invasive tumor with a poor prognosis. The prognostic factors of H3 K27M-mt DMG have not been fully identified, and there is no clinical prediction model for it. This study aimed to develop and validate a prognostic model for predicting the probability of survival in patients with H3 K27M-mt DMG. Patients diagnosed with H3 K27M-mt DMG in the West China Hospital from January 2016 to August 2021 were included. Cox proportional hazard regression was used for survival assessment, with adjustment for known prognostic factors. The final model was established using the patient data of our center as the training cohort and data from other centers for external independent verification. One hundred and five patients were ultimately included in the training cohort, and 43 cases from another institution were used as the validation cohort. The factors influencing survival probability in the prediction model included age, preoperative KPS score, radiotherapy and Ki-67 expression level. The adjusted consistency indices of the Cox regression model in internal bootstrap validation at 6, 12, and 18 months were 0.776, 0.766, and 0.764, respectively. The calibration chart showed high consistency between the predicted and observed results. The discrimination in external verification was 0.785, and the calibration curve showed good calibration ability. We identified the risk factors that affect the prognosis of H3 K27M-mt DMG patients and then established and validated a diagnostic model for predicting the survival probability of these patients.

Citing Articles

-New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates.

Singh G, Singh A, Bae J, Manjila S, Spektor V, Prasanna P Cancer Imaging. 2024; 24(1):133.

PMID: 39375809 PMC: 11460168. DOI: 10.1186/s40644-024-00769-6.

Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.

Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y Acta Neuropathol Commun. 2024; 12(1):120.

PMID: 39061104 PMC: 11282756. DOI: 10.1186/s40478-024-01808-w.

Diffuse midline (H3 K27M-mutant) glioma in adults-When resection fails to matter.

Zhang Y, Hudson K, Abounader R Neuro Oncol. 2024; 26(8):1494-1495.

PMID: 38829317 PMC: 11300008. DOI: 10.1093/neuonc/noae099.

Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration.

Huang B, Chen T, Zhang Y, Mao Q, Ju Y, Liu Y Brain Sci. 2023; 13(10).

PMID: 37891850 PMC: 10605651. DOI: 10.3390/brainsci13101483.

References

Chan K, Fang D, Gan H, Hashizume R, Yu C, Schroeder M . The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27(9):985-90. PMC: 3656328. DOI: 10.1101/gad.217778.113. View

Sanai N, Berger M . Surgical oncology for gliomas: the state of the art. Nat Rev Clin Oncol. 2017; 15(2):112-125. DOI: 10.1038/nrclinonc.2017.171. View

Lu V, Alvi M, McDonald K, Daniels D . Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis. J Neurosurg Pediatr. 2018; 23(3):308-316. DOI: 10.3171/2018.9.PEDS18419. View

Vuong H, Le H, Ngo T, Fung K, Battiste J, McNall-Knapp R . H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021; 155(3):225-234. DOI: 10.1007/s11060-021-03890-9. View

Enomoto T, Aoki M, Hamasaki M, Abe H, Nonaka M, Inoue T . Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis. Neurol Med Chir (Tokyo). 2020; 60(3):136-146. PMC: 7073699. DOI: 10.2176/nmc.oa.2019-0168. View

Cooney T, Lubanszky E, Prasad R, Hawkins C, Mueller S . Diffuse midline glioma: review of epigenetics. J Neurooncol. 2020; 150(1):27-34. DOI: 10.1007/s11060-020-03553-1. View

Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones D, Konermann C . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425-37. DOI: 10.1016/j.ccr.2012.08.024. View

Alzoubi H, Maraqa B, Hasasna N, Giangaspero F, Antonelli M, Gianno F . Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review. Clin Neuropathol. 2020; 40(2):108-117. DOI: 10.5414/NP301331. View

Gwak H, Park H . Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol. 2017; 120:111-119. DOI: 10.1016/j.critrevonc.2017.10.013. View

10.

Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N . Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015; 130(6):815-27. PMC: 4654747. DOI: 10.1007/s00401-015-1478-0. View

11.

Bender S, Tang Y, Lindroth A, Hovestadt V, Jones D, Kool M . Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013; 24(5):660-72. DOI: 10.1016/j.ccr.2013.10.006. View

12.

Zhu Q, Liang Y, Fan Z, Liu Y, Zhou C, Zhang H . Development and validation of a novel survival prediction model for newly diagnosed lower-grade gliomas. Neurosurg Focus. 2022; 52(4):E13. DOI: 10.3171/2022.1.FOCUS21596. View

13.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

14.

Zheng L, Zhang M, Hou J, Gong J, Nie L, Chen X . High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. Neuropathology. 2020; 40(6):599-605. DOI: 10.1111/neup.12672. View

15.

Feng J, Hao S, Pan C, Wang Y, Wu Z, Zhang J . The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol. 2015; 46(11):1626-32. DOI: 10.1016/j.humpath.2015.07.002. View

16.

Niu X, Yang Y, Zhou X, Zhang H, Zhang Y, Liu Y . A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort. Neuro Oncol. 2020; 23(2):337-338. PMC: 7906053. DOI: 10.1093/neuonc/noaa268. View

17.

Thompson E, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S . Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016; 17(4):484-495. PMC: 4907853. DOI: 10.1016/S1470-2045(15)00581-1. View

18.

Han M, Huang B, Ni S, Wang J, Li X, Bjerkvig R . A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort. Neuro Oncol. 2020; 22(5):729-731. PMC: 7229241. DOI: 10.1093/neuonc/noaa027. View

19.

Hassan U, Latif M, Yousaf I, Bin Anees S, Mushtaq S, Akhtar N . Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation. Cureus. 2021; 13(8):e17267. PMC: 8448278. DOI: 10.7759/cureus.17267. View

20.

Zheng L, Gong J, Yu T, Zou Y, Zhang M, Nie L . Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases. Am J Surg Pathol. 2022; 46(6):863-871. PMC: 9093723. DOI: 10.1097/PAS.0000000000001897. View